Indication: Chronic Myeloid Leukemia (CML)
AAML1921-ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia
Sub-indication: Chronic Myeloid Leukemia (CML)
Study Type: Drug Study
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Children's Oncology Group (COG)
Learn more at ClinicalTrials.gov
Email for more information: NCRI-Cancer@NortonHealthcare.org
